TABLE 3

Effect of oleate, alone or with PPAR-γ agonist or PPAR-γ antagonist*

Preincubation (48 h)Insulin in medium (ng/ml)
Insulin content (μg/ml)
Ratio
3.37.51120P3.37.51120P3.37.51120P
[11 mmol/l]G15 ± 175 ± 3103 ± 6105 ± 92.6 ± 0.12.3 ± 0.12.3 ± 0.12.5 ± 0.10.6 ± 0.13.1 ± 0.24.3 ± 0.34.1 ± 0.4
[11 mmol/l]G + ole29 ± 393 ± 6148 ± 8235 ± 163.0 ± 0.12.7 ± 0.12.6 ± 0.12.8 ± 0.20.9 ± 0.23.3 ± 0.25.4 ± 0.47.8 ± 0.3
[11 mmol/l]G + ole + [0.4 μmol/l]γ22 ± 388 ± 4128 ± 6129 ± 13§2.7 ± 0.22.5 ± 0.12.8 ± 0.23.0 ± 0.20.8 ± 0.13.4 ± 0.24.3 ± 0.14.1 ± 0.4§
[11 mmol/l]G + ole + [0.4 mmol/l]SR22 ± 255 ± 357 ± 553 ± 3§2.6 ± 0.22.5 ± 0.22.5 ± 0.22.5 ± 0.2NS0.8 ± 0.12.3 ± 0.32.4 ± 0.42.1 ± 0.2§
  • * n = 83, 27, 24, and 36 for each of the four rows.

  • P < 0.0001 and

  • P < 0.001 vs. [11 mmol/l]G;

  • § P < 0.0001 vs. [11 mmol/l]G + ole;

  • P < 0.0001 vs. [11 mmol/l]G + ole + [0.4 μmol/l]γ. [11 mmol/l]G, 11 mmol/l glucose; ole, 1 mmol/l oleate; [0.4 μmol/l]γ, 0.4 μmol/l Ro4389679-000-001 (PPAR-γ agonist); [0.4 mmol/l]SR, 0.4 mmol/l SR202(PPAR-γ antagonist).